Newsroom - ARTES Biotechnology GmbH

Pressemitteilungen

ARTES and BioSun announce co-development for HPV vaccine

, Biotechnik

ARTES Biotechnology and BioSun Pharmed announced to join forces for the development and manufacturing of a HPV (human papilloma virus) vaccine...

ARTES and Burnet Institute join forces to develop novel hepatitis C vaccine

, Biotechnik

ARTES Biotechnology and Burnet Institute announce they have joined forces to develop a novel, effective vaccine to prevent transmission of hepatitis...

ARTES Biotechnology and Biosphere announce collaboration

, Biotechnik

ARTES Biotechnology, specialized in microbial cell line and process development for recombinant protein production and technology provider for...

ARTES Biotechnology and Boehringer Ingelheim Animal Health Announce Collaboration

, Kooperationen / Fusionen

ARTES Biotechnology, specialized in recombinant protein production, process and vaccine development from microbial expression systems announces...

ARTES Biotechnology, instrAction and Q-Biologicals Join Forces for Veterinary Vaccine Development

, Biotechnik

B3C newswire / -[/b] ARTES Biotechnology, InstrAction and Q-Biologicals establish a three-party consortium for vaccine developments for veterinary...

Malaria Transmission-blocking Vaccines

, Biotechnik

. - ARTES Biotechnology and Burnet Institute have joined forces to develop a new type of malaria vaccine in a project funded by the PATH Malaria...

ARTES Biotechnology and Bio Farma Announce Collaboration in Vaccine Development

, Biotechnik

ARTES and Bio Farma announced today to join forces for the development and manufacturing of vaccine candidates. The agreed collaboration involved...

ARTES Biotechnology and Midas Pharma signed Cooperation Contract

, Biotechnik

ARTES Biotechnology announced the collaboration with Midas Pharma for strategic marketing opportunities. Aim of the cooperation is the finding...

ARTES Biotechnology issued New Patent in Australia for VLP Technology

, Biotechnik

ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry...

Strategic cooperation between ARTES Biotechnology and PAC

, Biotechnik

Artes and PAC join forces and combine their technologies and know-how. ARTES Biotechnology specializes in recombinant protein production, process...

ARTES Announces a Strategic Collaboration Deal for Vaccine Development

, Biotechnik

ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development...

ARTES Steps Further Into the Vaccine Business by Acquiring Anavax

, Biotechnik

ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a...

Injectable Sustained Release Formulations of Therapeutic Proteins

, Biotechnik

Q Chip Ltd and ARTES Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained...

Erfolgreiche Zusammenarbeit zwischen ARTES und Rhein Minapharm wird fortgeführt

, Firmenintern

ARTES Biotechnology GmbH, Spezialist für die Entwicklung rekombinanter Proteine und Prozesse in Hefen, und Rhein Minapharm Biogenetics, eine...

ARTES and Rhein Minapharm continue their successful product development collaboration

, Firmenintern

ARTES Biotechnology, specialized in recombinant protein production and process development from yeast expression systems, and Rhein Minapharm...

Media

Daten werden geladen, bitte warten...
Daten werden geladen, bitte warten...
Daten werden geladen, bitte warten...
Daten werden geladen, bitte warten...
ARTES Biotechnology GmbH
Elisabeth-Selbert-Str. 9
D - 40764 Langenfeld




Ansprechpartner

Frau Dr. Melanie Piontek


Business Development Director
ARTES Biotechnology

Telefon +49 (2173) 2758712


Herr Dr Ali Eram


Commercial Manager

Telefon +98 (0) 2188219500-2


alle Ansprechpartner

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.


Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.